GSK (NYSE:GSK) Upgraded by Berenberg Bank to "Buy" Rating

Key Points

• Berenberg upgraded GSK from “Hold” to “Buy,” although the broader analyst consensus remains “Hold,” with an average price target of $56.50.
• GSK’s latest quarterly results exceeded expectations: adjusted EPS was $1.36 versus the $1.27 consensus, while revenue rose 5.3% year over year to $11.14 billion.
• The company is expanding its oncology pipeline through positive lung-cancer data and acquisitions, including a potential $750 million deal for a multiple-myeloma therapy, while also planning to close a German flu-vaccine manufacturing site.

GSK (NYSE:GSK - Get Free Report) was upgraded by equities researchers at Berenberg Bank from a "hold" rating to a "buy" rating in a research report issued on Tuesday, Briefing.com reports.

Several other equities research analysts have also recently commented on GSK. HSBC reissued a "hold" rating on shares of GSK in a research note on Thursday. Weiss Ratings downgraded shares of GSK from a "buy (b-)" rating to a "hold (c+)" rating in a research report on Wednesday, July 29th. Citigroup started coverage on shares of GSK in a research note on Friday, July 24th. They issued a "neutral" rating on the stock. Jefferies Financial Group raised shares of GSK to a "strong-buy" rating in a research note on Friday, July 17th. Finally, Morgan Stanley restated an "underweight" rating on shares of GSK in a report on Tuesday, August 25th. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, seven have given a Hold rating and two have given a Sell rating to the company's stock. Based on data from MarketBeat.com, GSK presently has an average rating of "Hold" and an average target price of $56.50.

GSK Stock Up 4.0%

NYSE GSK opened at $50.07 on Tuesday. The stock's 50 day simple moving average is $51.22 and its 200 day simple moving average is $52.68. GSK has a one year low of $39.29 and a one year high of $61.69. The firm has a market cap of $101.27 billion, a PE ratio of 15.66, a price-to-earnings-growth ratio of 2.02 and a beta of 0.35. The company has a debt-to-equity ratio of 0.81, a current ratio of 0.82 and a quick ratio of 0.52.

GSK (NYSE:GSK - Get Free Report) last posted its quarterly earnings data on Tuesday, July 28th. The pharmaceutical company reported $1.36 EPS for the quarter, topping analysts' consensus estimates of $1.27 by $0.09. GSK had a return on equity of 43.23% and a net margin of 14.56%.The company had revenue of $11.14 billion for the quarter, compared to analyst estimates of $11.02 billion. During the same quarter in the previous year, the firm earned $0.47 earnings per share. The business's revenue was up 5.3% on a year-over-year basis. GSK has set its FY 2026 guidance at 4.900-5.000 EPS. As a group, sell-side analysts forecast that GSK will post 4.81 earnings per share for the current fiscal year.

Institutional Investors Weigh In On GSK

Several large investors have recently bought and sold shares of the company. Keystone Financial Planning Inc. boosted its stake in GSK by 3,114.8% in the 2nd quarter. Keystone Financial Planning Inc. now owns 195,590 shares of the pharmaceutical company's stock worth $10,253,000 after purchasing an additional 189,506 shares during the period. Sequoia Financial Advisors LLC increased its holdings in GSK by 1.8% during the 2nd quarter. Sequoia Financial Advisors LLC now owns 36,293 shares of the pharmaceutical company's stock worth $1,902,000 after purchasing an additional 641 shares in the last quarter. Tidal Investments LLC raised its stake in shares of GSK by 4.6% in the 2nd quarter. Tidal Investments LLC now owns 220,236 shares of the pharmaceutical company's stock valued at $11,545,000 after purchasing an additional 9,603 shares during the period. WINTON GROUP Ltd acquired a new stake in shares of GSK in the 2nd quarter valued at about $603,000. Finally, RFG Advisory LLC lifted its holdings in shares of GSK by 10.6% in the second quarter. RFG Advisory LLC now owns 18,391 shares of the pharmaceutical company's stock valued at $964,000 after purchasing an additional 1,768 shares in the last quarter. Institutional investors own 15.74% of the company's stock.

More GSK News

Here are the key news stories impacting GSK this week:

• Positive Sentiment: GSK agreed to acquire a trispecific T-cell engager for multiple myeloma from China-based Chimagen Biosciences for up to $750 million, including upfront and milestone payments. The deal adds a potentially differentiated immuno-oncology asset to GSK’s pipeline. Reuters article
• Positive Sentiment: New data for Jideytro (zidesamtinib) showed a high response rate and durable disease control in first-line ROS1-positive non-small-cell lung cancer. GSK plans an expanded U.S. regulatory submission, potentially broadening the drug’s commercial opportunity. Zacks article
• Positive Sentiment: GSK reported encouraging late-stage lung-cancer results across its pipeline. Its B7-H3 antibody-drug conjugate produced a Phase III overall-survival benefit in relapsed disease, while the risankizumab-related program reportedly reduced the risk of death by 54% in a relapsed small-cell lung cancer study. These results support GSK’s broader oncology investment, including its $10.6 billion Nuvalent acquisition. The Pharma Letter article
• Neutral Sentiment: Management also highlighted healthcare-policy collaboration using data from China’s Greater Bay Area, but this initiative is unlikely to have a material near-term effect on earnings.
• Negative Sentiment: GSK plans to close a German flu-vaccine manufacturing site, a restructuring decision that may improve efficiency over time but creates near-term implementation costs and underscores pressure on parts of its vaccine operations. Fierce Pharma article

GSK Company Profile

GSK plc is a global biopharmaceutical company headquartered in Brentford, England. The company researches, develops and manufactures medicines and vaccines for the prevention and treatment of disease, serving patients and healthcare providers in markets around the world.

GSK focuses on specialty medicines and vaccines in areas including infectious diseases, HIV, respiratory disease, immunology and oncology. Its products include prescription medicines, long-acting treatments and vaccines designed to protect against diseases such as shingles, meningitis, influenza and respiratory syncytial virus (RSV).

The company was formed in 2000 through the merger of Glaxo Wellcome and SmithKline Beecham.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.